Relay Therapeutics (RLAY) Total Liabilities (2019 - 2026)

Relay Therapeutics (RLAY) has 8 years of Total Liabilities data on file, last reported at $57.4 million in Q1 2026.

• Quarterly Total Liabilities fell 26.64% year-over-year to $57.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $57.4 million (down 26.64% YoY) and the FY2025 annual result came in at $54.3 million, down 41.96% from the prior year.
• Total Liabilities climbed to $57.4 million in Q1 2026 per RLAY's latest filing, from $54.3 million in the prior quarter.
• Across five years, Total Liabilities topped out at $168.9 million in Q3 2022 and bottomed at $54.3 million in Q4 2025.
• The 5-year median for Total Liabilities is $93.5 million (2024), against an average of $102.9 million.
• The widest annual swing landed in 2022, when Total Liabilities surged 179.84%; it then plunged 41.96% in 2025.
• Tracing RLAY's Total Liabilities over 5 years: stood at $149.6 million in 2022, then tumbled by 38.5% to $92.0 million in 2023, then rose by 1.66% to $93.5 million in 2024, then sank by 41.96% to $54.3 million in 2025, then rose by 5.82% to $57.4 million in 2026.
• Per Business Quant, the three latest RLAY Total Liabilities figures stand at $57.4 million (Q1 2026), $54.3 million (Q4 2025), and $62.3 million (Q3 2025).

Peer Comparison